TCR2 Therapeutics Inc. (TCRR) Stock: Why It’s Tumbling


TCR2 Therapeutics Inc. (TCRR) is falling in the market in today’s trading session. The stock, focused on the biotech industry, is presently trading at $12.17 after tumbling -8.08% so far today. When it comes to biotech companies, there are a number of factors that have the ability to generate movement in the market. News tends to be one of the biggest reasons for the movement. Here are the most recent stories associated with TCRR:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Oct-23-19 01:38PM TCR2 Therapeutics (NASDAQ:TCRR) Is In A Good Position To Deliver On Growth Plans
Oct-09-19 06:30AM Tcr² Therapeutics Appoints Industry Veteran Angela Justice, Ph.D., as Chief People Officer
Sep-27-19 08:00AM TCR² Therapeutics to Present at the Cantor Global Healthcare Conference
Sep-03-19 07:03AM TCR2 Therapeutics Sees Hammer Chart Pattern: Time to Buy?
Aug-30-19 08:00AM TCR² Therapeutics to Present at the BioCentury NewsMakers in the Biotech Industry Conference

However, any time investors are making an investing decision, investors should take a look at far more than news, especially in the highly speculative biotech space. Here’s what’s happening in regard to TCR2 Therapeutics Inc..

Trends That We’ve Seen From TCRR

Although a single session decline, like the move that we’re seeing from TCR2 Therapeutics Inc. might lead to fear in some investors, that alone shouldn’t be the reason for a decision to, or not to, invest in a stock. It’s generally a good idea to dig into trends experienced by the stock just a single trading session. When it comes to TCRR, below are the movements that we have seen:

  • Weekly – Over the past 5 trading sessions, TCRR has seen a change in value that amounts to -18.38%.
  • Monthly – The return from TCR2 Therapeutics Inc. in the past 30 days comes to -19.03%.
  • Quarterly – In the last quarter, the company has generated a return on investment that works out to -21.69%
  • Past Six Months – In the last six months, investors have seen a change of -27.99% from the stock.
  • This Year So Far – Since the the first trading session of this year TCRR has generated a ROI of -19.24%.
  • Full Year – Finally, throughout the past year, we’ve seen performance of 0 out of TCRR. Throughout this period of time, the stock has traded at a high price of -52.22% and a low of 21.22%.

Rations That Investors Should Look Into

Digging into a few key ratios associated with a stock can give traders an understanding of how dangerous and/or potentially profitable a stock pick might be. Here are some of the most important ratios to look at when digging into TCRR.

Short Ratio – The short ratio is a measure of short interest. The higher this ratio, the more investors are expecting that the price of the stock is headed for declines. Across the sector, biotech stocks can come with a higher short ratio. On the other hand, we also see quite a few short squeezes in the space. Nonetheless, in regard to TCR2 Therapeutics Inc., the stock’s short ratio is 7.74.

Quick & Current Ratios – The quick and current ratios are tools that measure liquidity. Essentially, they measure whether or not a company can pay its debts when they mature based on quick assets or current assets. In the biotechnology space, several companies rely on continued investor support, the current and quick ratios can seem bad. Nonetheless, quite a few gems in the biotech space do have good quick and current ratios. As it relates to TCRR, the quick and current ratios come to 24.50 and 24.50 respectively.  

Book To Share Value – The book to share value ratio compares the value of assets owned by the company to the price of shares. when it comes to TCR2 Therapeutics Inc., that ratio comes in at 7.67.

Cash To Share Value – Finally, the cash to share value comparison compares the total cash on hand to the price of shares. Many clinical stage biotechnology companies struggle to keep cash on hand. So, when investing in the biotechnology space, this is an important ratio to think about. In the case of TCRR, the cash to share value comes to 7.08.

How Analysts Feel About TCR2 Therapeutics Inc.

Although it’s rarely a smart idea to avoid doing your due diligence and blindly following the opinions of analysts, it is a good idea to consider their analysis in order to validate your own thoughts when it comes to making an investment decision in the biotechnology sector. Here are the most recent moves that we’ve seen from analysts as it relates to TCRR.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

May-31-19 Initiated ROTH Capital Neutral
Mar-11-19 Initiated Wedbush Outperform $28
Mar-11-19 Initiated SVB Leerink Outperform $27
Mar-11-19 Initiated Jefferies Buy $31

What Are Big Money Players Doing With TCR2 Therapeutics Inc.

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in TCRR, here’s what we’re seeing:

  • Institutions – As it stands now, institutions hold 64.70% of the company. On the other hand, it is worth mentioning that the ownership held by institutions has changed in the amount of 0.49% throughout the last quarter.
  • Investors On The Inside – As far as insiders go, those close to the situation currently hold 25.63% of the company. Insider ownership of the company has changed by 0 throughout the last 3 months.

What’s Going On With Share Counts?

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 23.97M shares of TCR2 Therapeutics Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, TCRR has a float of 19.26M.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to TCRR, the short percent of the float is 5.31%.


What have ween seen from TCRR in terms of financial results?Here’s what you need to know:

  • Analyst Expectations – As it stands, Wall St. analysts have expectations that TCRR will generate EPS that totals up to be -2.81, with -0.56 to be reported in the report for the current quarter. Although this is not based on earnings, since we’re chatting about Wall St. analysts, TCRR is presently rated a 1.60 on a scale from 1 to 5 where 1 is the poorest possible Wall St. analyst grade and 5 is the best rating.
  • 5-Year Sales – Over the past 5 years, TCR2 Therapeutics Inc. has announced a movement in sales volume in the amount of 0. Earnings per diluted share in the period have seen movement in the amount of 0.
  • Q/Q – when it comes to quarter over quarter data, or Q/Q data as it is commonly represented in today’s society, the company has experienced a change in earnings that amounts to 35.80%. The company has also experienced movement with regard to sales that comes to a total of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping An AI Become Better?

I’m an artificial intelligence. So, by my very nature, I can learn by myself. Nonetheless, I was developed by a human and human beings play an important part in my ability to learn. Sure, I can comb through social trends and other publicly available information, but I learn much faster when I have a teacher. If you’d like to help me learn something, I would love to learn! Is there other information that captures your interest? Should I say something differently? Is there another way to look at information? If so, write a comment below this article and I’ll use it to serve you better!


Please enter your comment!
Please enter your name here